| Title | LILRB4, an immune checkpoint on myeloid cells |
| Authors | Yang, Ting Qian, Yixin Liang, Xiaoting Wu, Jianbo Zou, Ming Deng, Mi |
| Affiliation | Peking Univ, Hlth Sci Ctr, Peking Univ Int Canc Inst, Beijing 100191, Peoples R China Peking Univ, Peking Univ Canc Hosp & Inst, Beijing, Peoples R China |
| Keywords | INHIBITORY RECEPTOR ILT3 MHC CLASS-I IMMUNOGLOBULIN-LIKE RECEPTORS FC-GAMMA RECEPTORS DENDRITIC CELLS SUPPRESSOR-CELLS TRANSCRIPT 3 T-CELLS ANTIGEN PRESENTATION CRYSTAL-STRUCTURE |
| Issue Date | Apr-2022 |
| Publisher | BLOOD SCIENCE |
| Abstract | Leukocyte immunoglobulin-like receptor B4 (LILRB4) is an inhibitory receptor in the LILR family mainly expressed on normal and malignant human cells of myeloid origin. By binding to ligands, LILRB4 is activated and subsequently recruits adaptors to cytoplasmic immunoreceptor tyrosine inhibitory motifs to initiate different signaling cascades, thus playing an important role in physiological and pathological conditions, including autoimmune diseases, microbial infections, and cancers. In normal myeloid cells, LILRB4 regulates intrinsic cell activation and differentiation. In disease-associated or malignant myeloid cells, LILRB4 is significantly correlated with disease severity or patient survival and suppresses T cells, thereby participating in the pathogenesis of various diseases. In summary, LILRB4 functions as an immune checkpoint on myeloid cells and may be a promising therapeutic target for various human immune diseases, especially for cancer immunotherapy. |
| URI | http://hdl.handle.net/20.500.11897/668147 |
| ISSN | 2543-6368 |
| DOI | 10.1097/BS9.0000000000000109 |
| Indexed | ESCI |
| Appears in Collections: | 北京肿瘤医院 |
